K Jobski1, J Höfer1, F Hoffmann1, C Bachmann2. 1. Department of Health Services Research, Carl von Ossietzky University Oldenburg, Oldenburg, Germany. 2. Faculty of Medicine, Philipps University Marburg, Marburg, Germany.
Abstract
OBJECTIVE: The objective of this review was to examine prevalence and patterns of psychopharmacotherapy in individuals with autism spectrum disorder (ASD). METHOD: A systematic literature search in PubMed, CINAHL, and PsycINFO was performed, including articles published up to November 18, 2015. RESULTS: A total of 47 studies (data collection: 1976-2012), encompassing >300 000 individuals with ASD, were included. The prevalence of psychopharmacotherapy ranged from 2.7% to 80% (median (overall): 45.7%; median (children): 41.9%; median (adults): 61.5%), with psychotropic polypharmacy occurring in 5.4-54% (median: 23.0%). Regarding drug classes, antipsychotics were most frequently used, followed by attention-deficit/hyperactivity disorder (ADHD) medication and antidepressants. Both older age and psychiatric comorbidity were associated with higher prevalences of psychopharmacotherapy and psychotropic polypharmacy. There were no time trends in psychopharmacotherapy prevalence observable. CONCLUSION: Despite a lack of pharmacological treatment options for ASD core symptoms, the prevalence of psychopharmacotherapy and polypharmacy in ASD patients is considerable, which is probably due to the treatment of non-core ASD symptoms and psychiatric comorbidities. While there is some evidence for the use of antipsychotics and ADHD medication for these indications, the use of antidepressants should be limited to selected cases.
OBJECTIVE: The objective of this review was to examine prevalence and patterns of psychopharmacotherapy in individuals with autism spectrum disorder (ASD). METHOD: A systematic literature search in PubMed, CINAHL, and PsycINFO was performed, including articles published up to November 18, 2015. RESULTS: A total of 47 studies (data collection: 1976-2012), encompassing >300 000 individuals with ASD, were included. The prevalence of psychopharmacotherapy ranged from 2.7% to 80% (median (overall): 45.7%; median (children): 41.9%; median (adults): 61.5%), with psychotropic polypharmacy occurring in 5.4-54% (median: 23.0%). Regarding drug classes, antipsychotics were most frequently used, followed by attention-deficit/hyperactivity disorder (ADHD) medication and antidepressants. Both older age and psychiatric comorbidity were associated with higher prevalences of psychopharmacotherapy and psychotropic polypharmacy. There were no time trends in psychopharmacotherapy prevalence observable. CONCLUSION: Despite a lack of pharmacological treatment options for ASD core symptoms, the prevalence of psychopharmacotherapy and polypharmacy in ASDpatients is considerable, which is probably due to the treatment of non-core ASD symptoms and psychiatric comorbidities. While there is some evidence for the use of antipsychotics and ADHD medication for these indications, the use of antidepressants should be limited to selected cases.
Authors: Mikkel Højlund; Anton Pottegård; Erik Johnsen; Rune A Kroken; Johan Reutfors; Povl Munk-Jørgensen; Christoph U Correll Journal: Br J Clin Pharmacol Date: 2019-05-11 Impact factor: 4.335
Authors: Aristotle N Voineskos; Benoit H Mulsant; Erin W Dickie; Nicholas H Neufeld; Anthony J Rothschild; Ellen M Whyte; Barnett S Meyers; George S Alexopoulos; Matthew J Hoptman; Jason P Lerch; Alastair J Flint Journal: JAMA Psychiatry Date: 2020-07-01 Impact factor: 21.596
Authors: Craige C Wrenn; Eric French; Dustin Baker; Randall McCallian; Ryan Kirk; Mark P Reilly; Maria G Valdovinos Journal: Psychopharmacology (Berl) Date: 2021-01-15 Impact factor: 4.530
Authors: K E Bethin; L G Kanapka; L M Laffel; S Majidi; N S Chaytor; S MacLeish; R Adams; N C Foster Journal: Diabet Med Date: 2019-07-25 Impact factor: 4.359
Authors: Hang Thi Nguyet Pham; Hong Nguyen Tran; Xoan Thi Le; Ha Thi Do; Tue Trong Nguyen; Chien Le Nguyen; Hideki Yoshida; Masamistu Yamaguchi; Folk R William; Kinzo Matsumoto Journal: Neurochem Res Date: 2021-05-05 Impact factor: 3.996
Authors: Ivan Gentile; Emanuela Zappulo; Maria Pia Riccio; Sandro Binda; Laura Bubba; Laura Pellegrinelli; Domenico Scognamiglio; Francesca Operto; Lucia Margari; Guglielmo Borgia; Carmela Bravaccio Journal: In Vivo Date: 2017 May-Jun Impact factor: 2.155